Literature DB >> 32649766

Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.

Monica Kasbekar1, Valentina Nardi2, Paola Dal Cin3, Andrew M Brunner4, Meghan Burke4, Yi-Bin Chen5, Christine Connolly4, Amir T Fathi4, Julia Foster4, Molly Macrae4, Steven L McAfee5, Kristin McGregor6, Rupa Narayan4, Aura Y Ramos4, Tina T Som4, Meghan Vartanian4, Robb S Friedman6, Karim A Benhadji7, Gabriela S Hobbs4.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32649766      PMCID： PMC7362377          DOI： 10.1182/bloodadvances.2020002308

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  22 in total

1.  PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.

Authors:  A Murati; V Gelsi-Boyer; J Adélaïde; C Perot; P Talmant; S Giraudier; L Lodé; A Letessier; B Delaval; V Brunel; M Imbert; R Garand; L Xerri; D Birnbaum; M J Mozziconacci; M Chaffanet
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

2.  Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

Authors:  Guilin Tang; John Kennedy Sydney Sir Philip; Olga Weinberg; Wayne Tam; Sam Sadigh; Jonathan I Lake; Elizabeth M Margolskee; Heesun J Rogers; Roberto N Miranda; Carlos Bueso-Ramos C; Eric D Hsi; Attilio Orazi; Robert P Hasserjian; Daniel A Arber; Adam Bagg; Sa A Wang
Journal:  Mod Pathol       Date:  2018-11-06       Impact factor: 7.842

Review 3.  The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.

Authors:  D Macdonald; A Reiter; N C P Cross
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

4.  A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5).

Authors:  Muna Ghazzawi; Varun Mehra; Marcin Knut; Loretta Brown; William Tapper; Andrew Chase; Hugues de Lavallade; Nicholas C P Cross
Journal:  Acta Haematol       Date:  2017-11-24       Impact factor: 2.195

5.  Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.

Authors:  S Verstovsek; V Subbiah; L Masarova; C Cameron Yin; G Tang; T Manshouri; E Asatiani; N G Daver
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

Review 6.  Targeting FGFR Signaling in Cancer.

Authors:  Mehdi Touat; Ecaterina Ileana; Sophie Postel-Vinay; Fabrice André; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2015-06-15       Impact factor: 12.531

Review 7.  Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.

Authors:  N Savage; T I George; J Gotlib
Journal:  Int J Lab Hematol       Date:  2013-03-13       Impact factor: 2.877

8.  Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

Authors:  Sergei Roumiantsev; Daniela S Krause; Carola A Neumann; Christopher A Dimitri; Frances Asiedu; Nicholas C P Cross; Richard A Van Etten
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

Review 9.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 10.  Blood and Bone Marrow Evaluation for Eosinophilia.

Authors:  Daniel F Boyer
Journal:  Arch Pathol Lab Med       Date:  2016-10       Impact factor: 5.534
View more
  4 in total

Review 1.  Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.

Authors:  Rory M Shallis; Alexa J Siddon; Amer M Zeidan
Journal:  Curr Hematol Malig Rep       Date:  2021-04-22       Impact factor: 3.952

2.  Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates HOXA9 Gene Expression in t(4;11) Leukemia Cells.

Authors:  Tiziana Fioretti; Armando Cevenini; Mariateresa Zanobio; Maddalena Raia; Daniela Sarnataro; Fabio Cattaneo; Rosario Ammendola; Gabriella Esposito
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

3.  Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Nienke Zinger; Luuk Gras; Rodrigo Martino; Emmanouil Nikolousis; Jürgen Finke; Anabelle Chinea; Alessandro Rambaldi; Marie Robin; Riccardo Saccardi; Annalisa Natale; John A Snowden; Panagiotis Tsirigotis; Carlos Vallejo; Gerald Wulf; Blanca Xicoy; Domenico Russo; Johan Maertens; Etienne Daguindau; Stig Lenhoff; Patrick Hayden; Tomasz Czerw; Donal P McLornan; Ibrahim Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2022-01-23       Impact factor: 5.174

4.  A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.

Authors:  Baohuan Cai; Yun Liu; Yating Chong; Stephanie Fay Mori; Atsuko Matsunaga; Hualei Zhang; Xuexiu Fang; Chang-Sheng Chang; John K Cowell; Tianxiang Hu
Journal:  Mol Cancer       Date:  2022-07-29       Impact factor: 41.444
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.